Sat, Aug 30, 2014, 6:18 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • fudfighter4 fudfighter4 Nov 22, 2012 3:41 PM Flag

    Arikace as a last-resort therapy for pneumonia

    For those here who believe I'm completely out of my tree in suggesting Arikace could be established as the gold standard therapy for people critically ill with pneumonia - the key phrase is "critically ill".

    I'm not suggesting Arikace will displace the drugs routinely used in the treatment of pneumonia. But if anything like sixteen million Chinese are indeed currently dying from pneumonia every year, at least that number are critically ill with pneumonia every year.

    The route of delivery of Arikace gives it a significant edge over any routine therapy administered either by tablet or injection, in that Arikace delivers an effective concentration of the antibiotic to the pulmonary bacterial infection far more quickly than is possible with drugs delivered via the bloodstream.

    But how suited is Arikace as a therapy for pneumonia in general? From the Wiki page for Bacterial pneumonia -

    "Gram-positive

    Streptococcus pneumoniae (J13) is the most common bacterial cause of pneumonia in all age groups except newborn infants. Streptococcus pneumoniae is a Gram-positive bacterium that often lives in the throat of people who do not have pneumonia.

    Other important Gram-positive causes of pneumonia are Staphylococcus aureus (J15.2) and Bacillus anthracis.

    Gram-negative

    Gram-negative bacteria are seen less frequently: Haemophilus influenzae (J14), Klebsiella pneumoniae (J15.0), Escherichia coli (J15.5), Pseudomonas aeruginosa (J15.1), and Moraxella catarrhalis are the most common."

    From Transave US patent 7879351 -

    "The method of claim 9, wherein the pulmonary infection is a pseudomonas, P. aeruginosa, P. paucimobilis, P. putida, P. fluorescens, and P. acidovorans, staphylococcal, Methicillinresistant Staphylococcus aureus (MRSA), streptococcal, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Enterobacter, Serratia, Haemophilus, Yersinia pesos, Burkholderia pseudomallei, B. cepacia, B. gladioli, B. multivorans, B. vietnamiensis, Mycobacterium tuberculosis, M. avium complex (MAC), M. avium, M. intracellulare, M. kansasii, M. xenopi, M. marinum, M. ulcerans, M. fortuitum complex, M. fortuitum, or M. chelonei infection."

    China's first priority is to improve its healthcare infrastructure to a standard where people with HIV infection are promptly diagnosed and put on an antiretroviral regimen, so that their immune systems don't deteriorate to the level where death from pneumonia is the outcome. But that's easier said than done, and until it's accomplished one can't help but feel that Arikace would save millions of lives if the physicians had access to it.

    Is the funding available?

    "BEIJING, June 25 (Xinhua) -- Missions set in a three-year plan for China's healthcare reform program in the 2009-2011 period have been completed on schedule, according to a new official report.

    The report said the reform efforts have brought about progress toward giving all the country's citizens access to basic medical services.

    It was recently submitted to the State Council by the healthcare reform office under the State Council, according to a statement issued by the office on Monday.

    Between 2009 and 2011, China's central government invested 450.6 billion yuan (70.79 billion U.S. dollars) in the country's medical care services, the report said.

    It also promised more government investment in this field in the 12th Five Year Plan period (2011-2015)."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INSM
13.93+0.11(+0.80%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.